Anti-NMDA Receptor Encephalitis Clinical Pathway — Inpatient
Anti-NMDA Receptor Encephalitis Clinical Pathway — Inpatient
Abortive Medication Management
These are initial dose recommendations and can be titrated based on child-specific response.
Pediatric doses should not exceed adult dosing recommendations (initial or maximum). Please contact pharmacy with questions or concerns.
Alpha2-Adrenergic Agonist
Medication | Age | Initial Dose | Side Effects and Considerations |
---|---|---|---|
Clonidine | Pediatric | Enteral: 0.002-0.005 mg/kg/DOSE Max: 0.05 mg |
|
Adult | |||
Dexmedetomidine ICU only |
Pediatric | IV Bolus: 0.25-0.5 mcg/kg/DOSE Max: 25 mcg |
|
Adult |
Benzodiazepines
Medication | Age | Initial Dose | Side Effects and Considerations |
---|---|---|---|
Diazepam | Pediatric | IV; Enteral: 0.04-0.1 mg/kg/DOSE |
|
Adult | IV; Enteral: 2 mg | ||
Lorazepam | Pediatric | IV; Enteral: 0.05 mg/kg/DOSE | |
Adult | IV; Enteral: 1-2 mg | ||
Midazolam | Pediatric | IV: 0.05 mg/kg/DOSE | |
Adult | IV: 1-2 mg |
Opioids
Medication | Age | Initial Dose | Side Effects and Considerations |
---|---|---|---|
Morphine | Pediatric | IV: 0.05-0.1 mg/kg/DOSE Enteral: 0.1-0.2 mg/kg/DOSE |
|
Adult | IV: 2-4 mg Enteral: 5 mg |
||
Oxycodone | Pediatric | Enteral: 0.1 mg/kg/DOSE | |
Adult | Enteral: 5 mg |